These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36423374)

  • 1. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin.
    Furuya F; Fujita Y; Matsuo N; Minamino H; Oguri Y; Isomura N; Ikeda K; Takesue K; Li Y; Kondo A; Mano F; Inagaki N
    EBioMedicine; 2022 Dec; 86():104342. PubMed ID: 36423374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Albarrán OG; Ampudia-Blasco FJ
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
    Oldgren J; Laurila S; Åkerblom A; Latva-Rasku A; Rebelos E; Isackson H; Saarenhovi M; Eriksson O; Heurling K; Johansson E; Wilderäng U; Karlsson C; Esterline R; Ferrannini E; Oscarsson J; Nuutila P
    Diabetes Obes Metab; 2021 Jul; 23(7):1505-1517. PubMed ID: 33625777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS; van Baar MJB; van Bommel EJM; Iqbal Z; Krebber MM; Vallon V; Touw D; Hoorn EJ; Nieuwdorp M; Kramer MMH; Joles JA; Bjornstad P; van Raalte DH
    Clin J Am Soc Nephrol; 2022 May; 17(5):663-671. PubMed ID: 35322793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Mulder S; Hammarstedt A; Nagaraj SB; Nair V; Ju W; Hedberg J; Greasley PJ; Eriksson JW; Oscarsson J; Heerspink HJL
    Diabetes Obes Metab; 2020 Jul; 22(7):1157-1166. PubMed ID: 32115853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
    Yabiku K; Nakamoto K; Tsubakimoto M
    J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
    Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
    Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
    Horibe K; Morino K; Miyazawa I; Tanaka-Mizuno S; Kondo K; Sato D; Ohashi N; Ida S; Yanagimachi T; Yoshimura M; Itoh R; Murata K; Miura K; Arima H; Fujita Y; Ugi S; Maegawa H;
    Diabetes Res Clin Pract; 2022 Apr; 186():109781. PubMed ID: 35181350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.
    Herat LY; Ward NC; Magno AL; Rakoczy EP; Kiuchi MG; Schlaich MP; Matthews VB
    World J Gastroenterol; 2020 Jun; 26(23):3225-3235. PubMed ID: 32684737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.